What are the features of the device being developed by HICKY?

It is an innovative device that is stent-shaped without leads and uses wireless power supply technology, aiming to reduce patient burden.

What is Central Sleep Apnea (CSA)?

It is a sleep disorder that co-occurs in about 40% of heart failure patients and is a serious condition affecting sleep quality and prognosis.

What kind of investments does the Tokyo Wellness Impact Fund make?

It invests in startups that aim to solve social issues in the wellness domain, seeking to create social impact.

AI News NQ Analysis

Tokyo Wellness Impact Fund Invests in HICKY, Inc. for Development of Central Sleep Apnea Treatment Device

NQ Score 50/100

AI Summary (NQ-processed)

The Tokyo Wellness Impact Fund has invested in HICKY, Inc., a company developing an innovative stent-type nerve stimulation device for treating Central Sleep Apnea (CSA), aiming to improve the prognosis of heart failure patients.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What are the features of the device being developed by HICKY?: A: It is an innovative device that is stent-shaped without leads and uses wireless power supply technology, aiming to reduce patient burden.
Q: What is Central Sleep Apnea (CSA)?: A: It is a sleep disorder that co-occurs in about 40% of heart failure patients and is a serious condition affecting sleep quality and prognosis.
Q: What kind of investments does the Tokyo Wellness Impact Fund make?: A: It invests in startups that aim to solve social issues in the wellness domain, seeking to create social impact.